表没食子儿茶素没食子酸酯治疗多系统萎缩的安全性与有效性:PROMESA随机双盲安慰剂对照试验
PROMESA试验在德国12个中心纳入92例多系统萎缩患者,随机分配接受表没食子儿茶素没食子酸酯(EGCG)或安慰剂治疗48周。EGCG总体耐受良好,但部分患者出现肝毒性,建议剂量不超过1200 mg。
要点
- 48周EGCG治疗未延缓多系统萎缩疾病进展。
- EGCG组2例因肝毒性停药,剂量超过1200 mg不应使用。
- 两组死亡率相似,EGCG组4例、安慰剂组2例死亡。
核心结论
- 48周EGCG治疗未能改变多系统萎缩患者的疾病进展。
- EGCG总体耐受良好,但部分患者出现肝毒性,剂量超过1200 mg不应使用。
研究设计与样本
- 随机、双盲、平行组、安慰剂对照临床试验,在德国12个专科中心进行。
- 纳入92例年龄>30岁、符合很可能或可能多系统萎缩共识标准、可独立行走(Hoehn and Yahr分期1-3)的患者,随机1:1分配至EGCG组(47例)或安慰剂组(45例)。
- 给药方案:每日口服胶囊,4周每日1次400 mg,4周每日2次,40周每日3次,48周后洗脱4周。
- 主要终点为从基线至52周UMSARS运动检查评分变化。
主要发现
- EGCG组4例死亡,安慰剂组2例死亡。
- EGCG组2例因肝毒性停止治疗。
- 67例完成治疗,64例完成研究(其中1例有重大方案违背)。
临床怎么用
- EGCG不推荐用于延缓多系统萎缩疾病进展。
- 如使用EGCG,剂量不应超过1200 mg/日,并需监测肝毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple system atrophy is a rare neurodegenerative disease characterised by aggregation of α-synuclein in oligodendrocytes and neurons. The polyphenol epigallocatechin gallate inhibits α-synuclein aggregation and reduces associated toxicity. We aimed to establish if epigallocatechin gallate could safely slow disease progression in patients with multiple system atrophy. METHODS: We did a randomised, double-blind, parallel group, placebo-controlled clinical trial at 12 specialist centres in Germany. Eligible participants were older than 30 years; met consensus criteria for possible or probable multiple system atrophy and could ambulate independently (ie, were at Hoehn and Yahr stages 1-3); and were on stable anti-Parkinson's, anti-dysautonomia, anti-dementia, and anti-depressant regimens (if necessary) for at least 1 month. Participants were randomly assigned (1:1) to epigallocatechin gallate or placebo (mannitol) via a web-generated permuted blockwise randomisation list (block size=2) that was stratified by disease subtype (parkinsonism-predominant disease vs cerebellar-ataxia-predominant disease). All participants and study personnel were masked to treatment assignment. Participants were given one hard gelatin capsule (containing either 400 mg epigallocatechin gallate or mannitol) orally once daily for 4 weeks, then one capsule twice daily for 4 weeks, and then one capsule three times daily for 40 weeks. After 48 weeks, all patients underwent a 4-week wash-out period. The primary endpoint was change in motor examination score of the Unified Multiple System Atrophy Rating Scale (UMSARS) from baseline to 52 weeks. Efficacy analyses were done in all people who received at least one dose of study medication. Safety was analysed in all people who received at least one dose of the study medication to which they had been randomly assigned. This trial is registered with ClinicalTrials.gov (NCT02008721) and EudraCT (2012-000928-18), and is completed. FINDINGS: Between April 23, 2014, and Sept 3, 2015, 127 participants were screened and 92 were randomly assigned-47 to epigallocatechin gallate and 45 to placebo. Of these, 67 completed treatment and 64 completed the study (altough one of these patients had a major protocol violation). There was no evidence of a difference in the mean change from baseline to week 52 in motor examination scores on UMSARS between the epigallocatechin gallate (5·66 [SE 1·01]) and placebo (6·60 [0·99]) groups (mean difference -0·94 [SE 1·41; 95% CI -3·71 to 1·83]; p=0·51). Four patients in the epigallocatechin gallate group and two in the placebo group died. Two patients in the epigallocatechin gallate group had to stop treatment because of hepatotoxicity. INTERPRETATION: 48 weeks of epigallocatechin gallate treatment did not modify disease progression in patients with multiple system atrophy. Epigallocatechin gallate was overall well tolerated but was associated with hepatotoxic effects in some patients, and thus doses of more than 1200 mg should not be used. FUNDING: ParkinsonFonds Deutschland, German Parkinson Society, German Neurology Foundation, Lüneburg Foundation, Bischof Dr Karl Golser Foundation, and Dr Arthur Arnstein Foundation.
引用
- Levin J, Maaß S, Schuberth M, et al. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2019. PMID: 31278067. doi:10.1016/S1474-4422(19)30141-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。